ReviewFrontiers in immunology2026
The Janus face of tissue-resident memory T cells: dual programming in tumor immune surveillance and autoimmune pathology.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tissue-resident memory T cells (Trm) are a subset of memory T cells that establish residency in peripheral tissues and do not re-enter circulation under homeostasis, playing a central role in local immune responses. Recent studies have revealed that Trm cells play a dual role in immune protection and immunopathology: in the tumor microenvironment they can directly kill tumor cells and enhance the efficacy of immunotherapies, serving as key mediators of antitumor immunity; conversely, in autoimmune diseases they may persist long-term and drive chronic inflammation and tissue damage. This functional duality is closely linked to the microenvironmental signals, transcriptional programs, and metabolic states that shape Trm cells. This review systematically examines the developmental differentiation and molecular features of Trm cells, their bidirectional regulatory mechanisms in cancer and autoimmunity, and outlines the therapeutic potential and challenges of precision disease interventions targeting Trm cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.